NCT03999801
Long-term Follow-Up Study of RGX-314 and Fellow Eye Substudy
Enrolling by Invitation
PHASE2Ages 50+InterventionalTreatmentAbbVie
~865 participants
Updated 2024-06-17 on ClinicalTrials.gov
What's tested:RGX-314
At a glance
Recruiting sites
0 of 9 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Incidence of ocular adverse events and any serious adverse events in the study eye
Measured over 5 years inclusive of parent study
+1 more outcome measured
Conditions
Where it's being run
9 sites across 8 statesPennsylvania2
Arizona1
California1
Maryland1
Massachusetts1
Nevada1
Tennessee1
Texas1
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
What this trial measures
- Incidence of ocular adverse events and any serious adverse events in the study eye5 years inclusive of parent study
- Fellow eye substudy: Incidence of ocular adverse events and any serious adverse events in the fellow eye54 weeks